Highlights
• Fever, headache, myalgia, and photophobia are common; severe cases include meningitis and encephalitis.
• OROV can pass from mother to fetus, causing issues like microcephaly and stillbirths.
• Up to 70% of patients report recurring symptoms like headache and fatigue after initial recovery.
• Live attenuated vaccine candidate demonstrated safety and immunity in clinical trials.
• Real-time RT-PCR detects OROV with 93% efficacy during the acute phase within five days of symptom onset.
• Two deaths were reported in Bahia, Brazil, in 2024, marking the first confirmed OROV-related fatalities.
京公网安备11010802044758号
Comments on this article